Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Maxcyte (MXCT) EPS (Weighted Average and Diluted) (2020 - 2026)

Maxcyte has reported EPS (Weighted Average and Diluted) over the past 6 years, most recently at -$0.09 for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) rose 10.0% to -$0.09 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$0.43 through Dec 2025, down 22.86% year-over-year, with the annual reading at -$0.42 for FY2025, 7.69% down from the prior year.
  • EPS (Weighted Average and Diluted) was -$0.09 for Q4 2025 at Maxcyte, up from -$0.12 in the prior quarter.
  • Over five years, EPS (Weighted Average and Diluted) peaked at -$0.03 in Q3 2021 and troughed at -$0.12 in Q2 2025.
  • The 5-year median for EPS (Weighted Average and Diluted) is -$0.09 (2021), against an average of -$0.08.
  • Year-over-year, EPS (Weighted Average and Diluted) skyrocketed 55.56% in 2022 and then plummeted 175.0% in 2023.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.05 in 2021, then dropped by 0.0% to -$0.05 in 2022, then rose by 0.0% to -$0.05 in 2023, then crashed by 100.0% to -$0.1 in 2024, then rose by 10.0% to -$0.09 in 2025.
  • Per Business Quant, the three most recent readings for MXCT's EPS (Weighted Average and Diluted) are -$0.09 (Q4 2025), -$0.12 (Q3 2025), and -$0.12 (Q2 2025).